A practical reference on GHRH analogue: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-06-02 and is reviewed periodically as new material appears.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | G-protein-coupled receptor on pituitary somatotrophs |
| Half-life, long-acting form | Several days | Extended by covalent albumin binding |
| Half-life, short form | About 30 minutes | Cleared rapidly by peptidases and kidneys |
| Route in studies | Subcutaneous injection | Used in the published human trials |
| Main measured effect | Rise in GH and IGF-1 | Surrogate markers rather than clinical endpoints |
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The majority of Zaporizhian Cossacks who had remained loyal to Russia despite the destruction of Sich became known as Black Sea Cossacks. Both Azov and Black Sea Cossacks were resettled to colonize the Kuban steppe, a crucial foothold for Russian expansion in the Caucasus. In 1860, more Cossacks were resettled to the North Caucasus, and merged into the Kuban Cossack Host.
== Treatment == Most (>95%) infants with biliary atresia will undergo an operation designed to retain and salvage the native liver, restore bile flow, and reduce the level of jaundice. This is known as the Kasai procedure (after Morio Kasai, the Japanese surgeon who first developed the technique) or hepatoportoenterostomy. Although the procedure is not thought of as curative, it may relieve jaundice and stop liver fibrosis, allowing normal growth and development. Published series from Japan, North America, and the UK show that bilirubin levels will fall to normal values in about 50-55% of infants, allowing 40-50% to retain their own liver to reach the age of 5 and 10 years (and beyond). Liver transplantation is an option for those children whose liver function and symptoms fail to respond to a Kasai operation. Recent large-scale studies by Davenport et al. (Annals of Surgery, 2008) show that the age of the patient is not an absolute clinical factor affecting prognosis. The influence of age differs according to the disease etiology—i.e., whether biliary atresia is isolated, cystic (CBA), or accompanied by splenic malformation (BASM). It is widely accepted that corticosteroid treatment after a Kasai operation, with or without choleretics and antibiotics, has a beneficial effect on postoperative bile flow and can clear jaundice, but there is currently no consensus on the ideal dosing and duration of steroid use.
=== Allergic conditions === Setipiprant proved to be well tolerated and reasonably effective in reducing allergen-induced airway responses in asthmatic patient clinical trials. However, the drug, while supporting the concept that DP2 contributes to asthmatic disease, did not show sufficient advantage over existing drugs and was discontinued from further development for this application.
=== Serving chicken without antibiotics === In February 2014, Chick-fil-A announced plans to serve chicken raised without antibiotics in its restaurants nationwide within five years, the first fast-food restaurant to make this commitment. This was implemented by May 2019. Later the company stated that "to maintain supply of the high-quality chicken", they would shift from a policy of No Antibiotics Ever (NAE) to No Antibiotics Important To Human Medicine (NAIHM) starting in the spring of 2024. In March 2024, Chick-fil-A announced it would depart from the company's previous commitment of using only "antibiotic-free" chicken.
Maximum diversity often leads to maximum stress. In the end we survive, but only by the skin of our teeth. This is the confession of faith of a scientific heretic. Perhaps I may claim as evidence for progress in religion the fact that we no longer burn heretics.
Sources: en.wikipedia.org
==== MeSH D08.811.600 – multienzyme complexes ==== MeSH D08.811.600.075 – anthranilate phosphoribosyltransferase MeSH D08.811.600.085 – anthranilate synthase MeSH D08.811.600.116 – aspartate carbamoyltransferase MeSH D08.811.600.130 – aspartokinase homoserine dehydrogenase MeSH D08.811.600.200 – cholesterol side-chain cleavage enzyme MeSH D08.811.600.250 – electron transport chain complex proteins MeSH D08.811.600.250.500 – electron-transferring flavoproteins MeSH D08.811.600.250.500.500 – electron transport complex i MeSH D08.811.600.250.500.750 – electron transport complex ii MeSH D08.811.600.250.500.750.500 – succinate dehydrogenase MeSH D08.811.600.250.687 – electron transport complex iv MeSH D08.811.600.250.875 – succinate cytochrome c oxidoreductase MeSH D08.811.600.250.875.249 – electron transport complex ii MeSH D08.811.600.250.875.249.500 – succinate dehydrogenase MeSH D08.811.600.250.875.500 – electron transport complex iii MeSH D08.811.600.317 – fatty acid synthetase complex MeSH D08.811.600.391 – glycine decarboxylase complex MeSH D08.811.600.391.100 – aminomethyltransferase MeSH D08.811.600.391.150 – dihydrolipoamide dehydrogenase MeSH D08.811.600.391.175 – glycine decarboxylase complex h-protein MeSH D08.811.600.391.200 – glycine dehydrogenase (decarboxylating) MeSH D08.811.600.465 – ketoglutarate dehydrogenase complex MeSH D08.811.600.465.500 – dihydrolipoamide dehydrogenase MeSH D08.811.600.541 – lactose synthase MeSH D08.811.600.700 – phosphoenolpyruvate sugar phosphotransferase system MeSH D08.811.600.710 – photosynthetic reaction center complex proteins MeSH D08.811.600.710.249 – light-harvesting protein complexes MeSH D08.811.600.710.374 – cytochrome b6f complex MeSH D08.811.600.710.374.500 – cytochromes b6 MeSH D08.811.600.710.374.750 – cytochromes f MeSH D08.811.600.710.374.875 – plastoquinol-plastocyanin reductase MeSH D08.811.600.710.500 – photosystem i protein complex MeSH D08.811.600.710.750 – photosystem ii protein complex MeSH D08.811.600.715 – polyketide synthases MeSH D08.811.600.720 – prostaglandin-endoperoxide synthases MeSH D08.811.600.720.500 – cyclooxygenase 1 MeSH D08.811.600.720.750 – cyclooxygenase 2 MeSH D08.811.600.730 – proteasome endopeptidase complex MeSH D08.811.600.741 – pyruvate dehydrogenase complex MeSH D08.811.600.741.525 – dihydrolipoamide dehydrogenase MeSH D08.811.600.741.625 – dihydrolipoyllysine-residue acetyltransferase MeSH D08.811.600.741.725 – pyruvate dehydrogenase (lipoamide) MeSH D08.811.600.850 – sucrase-isomaltase complex MeSH D08.811.600.896 – tryptophan synthase
== External links == Eosinophil+Major+Basic+Protein at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Overview of all the structural information available in the PDB for UniProt: P13727 (Bone marrow proteoglycan) at the PDBe-KB.
Dinosterol (4α,23,24-trimethyl-5α-cholest-22E-en-3β-ol) is a 4α-methyl sterol that is produced by several genera of dinoflagellates and is rarely found in other classes of protists. The steroidal alkane, dinosterane, is the 'molecular fossil' of dinosterol, meaning that dinosterane has the same carbon skeleton as dinosterol, but lacks dinosterol's hydroxyl group and olefin functionality. As such, dinosterane is often used as a biomarker to identify the presence of dinoflagellates in sediments.
In biology, a pair bond is the strong affinity that develops in some species between a mating pair, often leading to the production and rearing of young and potentially a lifelong bond. Pair-bonding is a term coined in the 1940s that is frequently used in sociobiology and evolutionary biology circles. The term often implies either a lifelong socially monogamous relationship or a stage of mating interaction in socially monogamous species. It is sometimes used in reference to human relationships.
Sources: en.wikipedia.org
Mummies, though typically thought of as an Egyptian phenomenon, exist in many cultures and have been found on nearly every continent. The word mummy can refer to both intentionally and naturally preserved bodies and is not limited to one geographic area or culture. Damage of mummified remains can be caused by several factors, including poor environmental conditions, physical damage, and improper methods of preservation. Controlling environmental conditions is highly important in preserving the integrity of mummies. Fungi, pests, and microorganisms that cause decay are some of the possible results of inadequate storage and environmental factors. There are a number of ways to mitigate the effects of improper conditions, however. Methods of stabilizing mummies and halting deterioration include inert gas control, where the mummy is placed in a chamber or bag into which fumigants are introduced; wet sterilization, where solutions are applied to the mummy to repel insects and the growth of fungi; controlled drying, which reduces the relative humidity in order to stop growth of microorganisms; and ultraviolet irradiation, which kills microorganisms. Some previous treatments which were thought to help preserve mummified remains but ultimately led to further damage include curing remains by smoking them and applying solutions of copper salts to exposed skin. The Artefact Lab at the University of Pennsylvania Museum of Archaeology and Anthropology (Penn Museum) provides examples and images of mummy preservation.
San Francisco's progressive community tried to field a candidate to run against Newsom. Supervisors Ross Mirkarimi and Chris Daly considered running, but both declined. Gonzalez also decided not to challenge Newsom again. When the August 10, 2007, filing deadline passed, San Francisco's discussion shifted to talk about Newsom's second term. He was challenged in the election by 13 candidates, including George Davis, a nudist activist, and Michael Powers, owner of the Power Exchange sex club. Conservative former supervisor Tony Hall withdrew by early September due to lack of support. In August 2007, the San Francisco Chronicle wrote that Newsom faced no "serious threat to his re-election bid", having raised $1.6 million for his campaign by early August. He was reelected on November 6 with over 72% of the vote. Upon taking office for a second term, Newsom promised to focus on the environment, homelessness, health care, education, housing, and rebuilding San Francisco General Hospital.
The rate of proteolysis may also depend on the physiological state of the organism, such as its hormonal state as well as nutritional status. In time of starvation, the rate of protein degradation increases.
== Applications == Gas analysis: for determining small amounts of impurities or poisons in air. Other compounds can also be determined by this method (ozone, N-oxides, S-compounds). A typical example is NO determination with detection limits down to 1 ppb. Highly specialised chemiluminescence detectors have been used recently to determine concentrations as well as fluxes of NOx with detection limits as low as 5 ppt. Analysis of inorganic species in liquid phase Analysis of organic species: useful with enzymes, where the substrate is not directly involved in the chemiluminescence reaction, but the product is Detection and assay of biomolecules in systems such as ELISA and Western blots DNA sequencing using pyrosequencing Lighting objects. Chemiluminescence kites, emergency lighting, glow sticks (party decorations). Combustion analysis: Certain free radical species (such as •CH and •OH) give off radiation at specific wavelengths. The heat release rate is calculated by measuring the amount of light radiated from a flame at those wavelengths. Children's toys
== External links == The MEROPS online database for peptidases and their inhibitors: S01.223 Acrosin at the U.S. National Library of Medicine Medical Subject Headings (MeSH) This article incorporates text from the United States National Library of Medicine, which is in the public domain.
Sources: en.wikipedia.org
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.
The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.
Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.